Synthesis of New Bicyclic Hydroxamic Acids with Cytotoxic Activity

Iker S. Escalona-Torres,[1] Francisco Yuste,[1] and Rubén Sánchez-Obregón[1]*

[1]Instituto de Química, Universidad Nacional Autónoma de México. Circuito Exterior s/n. Ciudad Universitaria, Coyoacán 04510, Ciudad de México, México.
Corresponding author e-mail: rubens@unam.mx Tel.: +52 55 56224406; fax: +52 55 56162217.

Abstract. Six new bicyclic hydroxamic acids were synthesized through an uncommon nitro group rearrangement between β-nitrostyrenes and dimedone. The structures of all the new synthesized compounds were confirmed using a combination of FTIR, ^{1}H NMR, ^{13}C NMR and mass spectral data. Likewise, the cytotoxic activity of the obtained products was evaluated in six different cancer cell lines. Two compounds showed significant potency on two cancer cell lines with IC_{50} between 9.31±0.1 and 23.38±0.9 μM.
Key words: Hydroxamic acids; Michael addition; nitro group rearrangement; cytotoxic activity

Resumen. Se sintetizaron seis nuevos ácidos hidroxámicos bicíclicos a través de una transposición poco común del grupo nitro, entre β-nitroestirenos y dimedona. Las estructuras de todos compuestos sintetizados se determinaron mediante FTIR, ^{1}H NMR, ^{13}C RMN y espectrometría de masas. Asimismo, se evaluó la actividad citotóxica de los productos obtenidos en seis líneas celulares de diferentes tipos de cáncer. Dos compuestos mostraron actividad importante contra dos líneas celulares de cáncer con IC_{50} entre 9.31±0.1 y 23.38±0.9 μM.
Palabras clave: Ácidos hidroxámicos; adición de Michael; transposición del grupo nitro; actividad citotóxica.

Introduction

Hydroxamic acids whether acyclic or cyclic, are interesting compounds which contain a hydroxyl group on a nitrogen atom of an amide or a lactam group. They are found to be associated with various activities such as anti-HIV [1], anti-Alzheimer diseases [2], in the treatment of metal poisoning [3], malaria [4], allergic diseases [5], and tuberculosis [6]. Also, it has been reported that hydroxamic acids possess cytotoxic activity as result of the inhibition of the histone deacetylase (HDAC) enzyme [7]. Some hydroxamic acids are presented in Fig.1, and these compounds exert significant cytotoxic activity *in vitro*, especially on prostate cancer cells [8-10].

In the present work, we targeted the synthesis of several bicyclic hydroxamic acid derivatives, employing an uncommon nitro group rearrangement in the reaction between β-nitrostyrenes [11-14] and dimedone using a similar procedure to that reported by Larson et al [15]. The cytotoxicity of the obtained compounds was evaluated to establish its potential anticancer activity.

Results and Discussion

Chemistry

The β-nitrostyrenes **2** used for the synthesis of hydroxamic acids **3**, were prepared from a similar procedure [16], from nitromethane (1.1 equiv.), the corresponding benzaldehydes **1a-f** (1.0 equiv.) and $AcONH_4$ (0.4 equiv.) in glacial acetic acid under reflux for 2 h.


Fig. 1. Representative hydroxamic acids with HDAC inhibitory activity.

The intermediate nitrostyrenes (**2a-f**) were obtained in yields ranging from 91 to 95 % and their structures were determined by m.p., NMR and MS data. The β-nitrostyrenes **2a-f** were reacted with dimedone in the presence of 2.2 equiv. of MeONa in dry MeOH, under nitrogen at 35-40 °C, yielding the target hydroxamic acids **3a-f** (Scheme 1).

The mechanism whereby the hydroxamic acids **3a-f** are formed is not clear; a proposal is shown (Scheme2) supported by examples from literature [17, 18]. The Michael addition of dimedone anion to nitrostyrene would lead to intermediate **A**, which in the presence of methanol and the methoxide ion would produce the nitrile oxide **B**, which undergoes a hydroxyl group attack toward the triple bond of the nitrile oxide producing in-

termediate **C**. Finally, the protonation and dehydration reactions of this intermediate gives the compound **D** which shows a tautomeric equilibrium with the hydroxamic acid **3a**.

The chemical identification of products **3a-f** was carried out using FTIR, ^{1}H NMR, ^{13}C NMR and mass spectral data. Finally, the hydrogenation reaction for compound **3a** in the presence of Raney Nickel in ethanol produced compound **4**, and subsequent dehydrogenation with Pd/C led to the pyrrole **5** (Scheme 3), confirming the structure of 1-hydroxy-6,6-dimethyl-3-phenyl-3,5,6,7-tetrahydro-1*H*-indole-2,4-dione (**3a**) and probably the heterocyclic framework of the other products, instead of 2-hydroxyiminofuran derivatives [19].Additionally, to corroborate the structure of pyrrole **5**, it was prepared through a different synthetic route [20].

1a: R = H
1b: R = *o*-CH₃
1c: R = *o*-OCH₃
1d: R = *o*-Cl
1e: R = *p*-CH₃
1f: R = *p*-Br

Scheme 1. Synthesis of hydroxamic acids **3a-f.**

Scheme 2. Proposed mechanism for the formation of hydroxamic acids **3a.**

Scheme 3. Synthesis of pyrrole derivative (**5**) to confirm the structure of **3a**.

Cytotoxic activity

Cytotoxicity *in vitro* for compounds **3a-f** was evaluated in six cancer cell lines, such as K562 (leukemia), HCT-15 (colon), MCF-7 (breast), PC-3 (prostate), U251 (CNS) and SKLU-1 (lung), using the Sulforhodamine B assay as is described by the National Cancer Institute of the United States of America [21]. Preliminary screening with 50 µM solution of each compound allowed to determine that compounds **3a-f** were more active in PC-3 and SKLU-1 cell lines. Then the concentration for tested compounds resulted 50 % inhibition of cell proliferation (IC_{50}) was calculated. The results are summarized in the Table 1. In accordance with the IC_{50} values the compounds showed moderate cytotoxic activity against PC-3 and SKLU-1, among them **3e** (IC_{50} = 23.38±0.9 µM against PC-3 and 9.31±0.1 µM against SKLU-1) compared to suberoylanilide hydroxamic acid (SAHA), a drug used in cancer chemotherapy, IC_{50} = 0.91±0.04 µM and 0.91±0.09 µM, respectively, another compound which showed good cytotoxic activity was **3f** with IC_{50} values of 22.89±1.8 µM and 15.3±1.1 µM, for the respective cell lines (Tables 2-4, Figures 2-12). This suggests that the presence of substituent on 4′ of the aromatic ring plays an important role in the cytotoxicity in comparison with the substituent located at 2′ as in **3b-d** or when R is hydrogen (**3a**).

Table 1. Bicyclic hydroxamic acids and their cytotoxic activity *in vitro* against two cancer cell lines.

Entry	R	Compound	Yield/%	IC_{50}/µM	
				PC-3	SKLU-1
1	H	**3a**	80	45.26±1.8	20.41±0.9
2	*o*-CH$_3$	**3b**	72	>100	87.11±7.2
3	*o*-OCH$_3$	**3c**	75	a	a
4	*o*-Cl	**3d**	83	63.42±2.0	20.86±0.2
5	*p*-CH$_3$	**3e**	57	23.38±0.9	9.31±0.1
6	*p*-Br	**3f**	64	22.89±1.8	15.3±1.1
7		SAHA		0.91±0.0.04	0.091±0.09

[a]No activity

Table 2. Cytotoxic activity of SAHA.

| Cancer cell line	Concentration (µM)	Inhibition of the proliferation (%)			
PC-3	1.00	87.76	86.85	95.40	91.80
	3.10	73.98	75.37	74.80	72.20
	1.00	60.57	45.20	54.00	49.70
	0.31	29.51	35.37	23.30	32.70
SKLU-1	1.00	91.72	91.15	90.37	90.94
	3.10	83.78	80.61	78.52	82.30
	1.00	59.36	59.28	52.84	56.01
	0.31	27.36	25.14	14.94	28.59

Fig. 2. Relation between PC-3 inhibition percentage and log of concentration for SAHA (R^2 = 0.995).


Fig. 3. Relation between SKLU-1 inhibition percentage and log of concentration for SAHA (R^2 = 0.949).

Table 3. Cytotoxic activity of compounds **3a-f** in PC-3.

Compound	Concentration (µM)	Inhibition of the proliferation (%)				
3a	80.00	93.50	100.00	100.00	100.00	*
	60.00	81.80	96.70	53.90	53.87	*
	40.00	23.30	41.70	30.06	34.57	*
	20.00	0.00	0.00	0.52	18.71	*
3d	100.00	100.00	100.00	*	*	*
	80.00	63.60	76.30	*	*	*
	60.00	26.60	3.57	*	*	*
	40.00	13.20	15.70	*	*	*
3e	50.00	100.00	100.00	100.00	100.00	*
	25.00	44.60	47.90	78.28	77.11	*
	12.50	0.00	9.58	0.00	4.52	*
3f	50.00	100.00	100.00	100.00	100.00	100.00
	25.00	66.01	63.23	41.80	22.00	69.77
	12.50	17.30	20.46	4.08	0.00	10.87

*Unregistered data

Table 4. Cytotoxic activity of compounds **3a-f** in SKLU-1.

| Compound	Concentration (µM)	Inhibition of the proliferation (%)		
3a	50.00	100.00	100.00	92.92
	25.00	68.86	51.32	42.99
	12.50	10.07	22.69	26.95
	6.25	0.00	12.23	12.13
3b	100.00	82.09	82.51	94.04
	75.00	39.10	20.28	67.15
	50.00	20.75	11.12	59.35
	25.00	2.47	0.00	16.88
3d	50.00	96.38	77.54	80.87
	25.00	57.43	55.52	55.50
	12.50	19.67	28.92	24.38
	6.25	0.00	18.90	16.53
3e	25.00	98.59	95.07	95.90
	12.50	46.88	48.36	50.43
	6.25	32.42	27.73	27.34
	3.12	20.74	19.19	18.30
3f	50.00	100.00	100.00	100.00
	25.00	83.64	92.12	54.24
	12.50	31.60	41.64	35.56
	6.25	13.20	15.74	2.02

Fig. 4. Relation between SKLU-1 inhibition percentage and log of concentration for compound **3a** ($R^2 = 0.946$).


Fig. 5. Relation between PC-3 inhibition percentage and log of concentration for **3a** compound ($R^2 = 0.952$).


Fig. 6. Relation between SKLU-1 inhibition percentage and log of concentration for **3b** compound ($R^2 = 0.859$).

Fig. 7. Relation between PC-3 inhibition percentage and log of concentration for **3d** compound ($R^2 = 0.828$).

Fig. 8. Relation between SKLU-1 inhibition percentage and log of concentration for **3d** compound ($R^2 = 0.972$).

Fig. 9. Relation between PC-3 inhibition percentage and log of concentration for **3e** compound ($R^2 = 0.985$).

Fig. 10. Relation between SKLU-1 inhibition percentage and log of concentration for **3e** compound ($R^2 = 0.891$).


Fig. 11. Relation between PC-3 inhibition percentage and log of concentration for **3f** compound ($R^2 = 0.998$).


Fig. 12. Relation between SKLU-1 inhibition percentage and log of concentration for **3f** compound ($R^2 = 0.989$)

Conclusion

Six new bicyclic hydroxamic acids were synthesized in a two-step sequence starting from aromatic aldehydes **1**. The β-nitrostyrenes **2** were obtained by Henry reaction of **1** with nitromethane followed by their reaction with dimedone in basic medium, through an uncommon reaction of nitro group, to obtain the products **3** in good yields (57-80 %). The cytotoxicity of these compounds has been evaluated against different cancer cell lines. Thus, compounds **3e** and **3f** showed good cytotoxic activity.

Experimental

Materials

Starting materials and solvents were purchased from Sigma-Aldrich Co. and used without further purification. Melting points were determined using an Electrothermal Digital Melting Point Apparatus. IR spectra were measured using a Bruker Tensor 27 FT-IR spectrometer. ^{1}H NMR (300 MHz) and ^{13}C NMR (75 MHz) spectra were recorded in a Jeol Eclipse 300 MHz spectrometer using $CDCl_3$ as solvent and TMS as internal reference. Data for ^{1}H NMR are recorded as follows: chemical shift (δ/ppm); multiplicity: s: singlet, d: doublet, dd: double doublet, t: triplet, td: triple doublet, m: multiplet or unresolved, bs: broad signal; the coupling constants are expressed in Hz. Data for ^{13}C NMR are reported in terms of chemical shifts (δ/ppm). HR-EI-MS and HR-ESI-MS spectra were obtained in a Jeol M Station JMS-700 and a Jeol AccuTOF JMS-T-100 LC. Flash chromatography was performed with silica gel 60 (230-400 mesh ASTM). Silica gel 60 F_{254} aluminum plates were used for TLC analysis. Developing agents: phosphomolybdic acid 10 % in ethanol. The nitrostyrenes were synthesized following the reported procedure [16]. All products were purified by recrystallization.

General procedure for the synthesis of compounds 2a-f.

Each benzaldehyde (4 mmol) was treated with nitromethane (4.4 mmol), ammonium acetate (1.6 mmol) in glacial acetic acid (5 mL). The mixture was stirred and refluxed for 2 h and the reaction mixture was cooled to 0 °C. The obtained products were filtered off and recrystallized from ethanol to give **2a-f**. The ^{1}H and ^{13}C NMR spectra were in accordance to those cited in the literature for each described compound [12-14].

[(E)-1-(2-nitroethenyl)]benzene **(2a).** Isolated yield 92 %; yellowish solid; m.p.: 55-56 °C (from ethanol) (Ref. [12] 55-57 °C, Ref. [13] 59-62 °C). ^{1}H NMR (300 MHz, $CDCl_3$): δ= 7.43-7.32 (m, 2H, C*H*arom), 7.52-7.48 (m, 1H, C*H*arom), 7.57-7.53 (m, 2H, 2C*H*arom), 7.59 (d, *J* = 14 Hz, 1H, C*H* olefinic), 8.02 (d, 1H, *J* = 14 Hz, C*H* olefinic) ppm; ^{13}C NMR (75 MHz, $CDCl_3$): δ = 124.3, 129.6, 130.7, 131.5, 136.2, 139.5 ppm.

1-Methyl-2-[(E)-2-nitroethenyl]benzene **(2b).** Isolated yield 95 %; yellow solid; m.p.: 63-65 °C (from ethanol) (Ref. [13] 112-118 °C, Ref. [14] yellow oil). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 2.47 (s, 3H, CH_3), 7.27–7.24 (m, 2H, CH_2 arom), 7.39–7.35 (m, 1H, CH arom), 7.50–7.47 (m, 2H, CH olefinic, CH arom), 8.28 (d, J = 13.6 Hz, 1H, CH olefinic) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ =20.1, 126.9, 127.5, 129.1, 131.6, 132.1, 136.9, 137.8, 139.4 ppm.

1-Methoxy-2-[(E)-2-nitroethenyl]benzene **(2c).** Isolated yield 94 %; yellow solid; m.p.: 60-62 °C (from ethanol) (Ref. [14] 50-52 °C). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 3.98 (s, 3H, OCH_3), 7.06–6.99 (m, 2H, 2CH arom), 7.50–7.46 (m, 2H, 2CH arom), 7.91 (d, J = 13.6 Hz, 1H, CH olefinic), 8.16 (d, J = 13.6 Hz, 1H, CH olefinic) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 55.8, 111.6, 119.4, 121.3, 132.6, 133.6, 135.6, 138.5, 159.7 ppm.

1-Chloro-2-[(E)-2-nitroethenyl]benzene **(2d).** Isolated yield 91 %; brown solid; m.p.: 42-44 °C (from ethanol) (Ref. [12] 40-42, Ref. [14] 48-52 °C). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 7.36–7.32 (m, 1H, CH arom), 7.43 (td, J = 7.7, J = 1.5 Hz, 1H, CH arom), 7.50 (dd, J = 8.0, J = 1.1 Hz, 1H, CH arom), 7.61–7.57 (m, 2H, CH olefinic, CH arom), 8.41 (d, 1H, J = 13.7 Hz, CH olefinic) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 127.7, 128.7, 128.8, 130.9, 133.1, 135.3, 136.2, 139.1 ppm.

1-Methyl-4-[(E)-2-nitroethenyl]benzene **(2e).** Isolated yield 93 %; yellow solid; m.p.: 88-90 °C (from ethanol) (Ref. [12] 100-102 °C, Ref. [13] 102-106 °C, Ref. [14] 106-108 °C). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 2.44 (s, 3H, CH_3), 7.28 (d, J = 8.1 Hz, 2H, 2CH arom), 7.47 (d, J = 8.1 Hz, 2H, 2CH arom), 7.59 (d, J = 13.7 Hz, 1H, CH olefinic), 8.01 (d, J=13.7 Hz, 1H, CH olefinic) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 21.9, 127.4, 129.4, 130.3, 136.5, 139.4, 143.3 ppm.

1-Bromo-4-[(E)-2-nitroethenyl]benzene **(2f).** Isolated yield 95 %; light yellow solid; m.p.: 115-118 °C (from ethanol) (Ref. [12] 148-150 °C, Ref. [14] 153-155 °C). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 7.40 (d, 2H, J = 8.4 Hz, 2CH arom), 7.60–7.55 (m, 3H, CH olefinic, 2CH arom), 7.93 (d, J = 13.7 Hz, 1H, CH olefinic) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 127.0, 129.1, 130.6, 132.9, 137.6, 138.0 ppm.

General procedure for the synthesis of compounds 3a-f.

A solution of sodium methoxide (10.8 mmol) in anhydrous methanol (15 mL) was heated to 40 °C and 5,5-dimethylcyclohexane-1,3-dione (5.01 mmol) was added. To this solution were added the *o-*,*p*-substituted nitrostyrenes **(2a-f)** (5.01 mmol) and the mixture was stirred at 35-40 °C for 3 h, under nitrogen. Then, the mixture was cooled to 0 °C and acidified with 10 % hydrochloric solution until pH 3. The solid product was filtered off and recrystallized from hexane-acetone.

1-Hydroxy-6,6-dimethyl-3-phenyl-5,6,7,7a-tetrahydro-1H-indole-2,4-dione **(3a).** Isolated yield 80 %; beige crystals; m.p.: 145-148 °C (from hexane-acetone). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.14 (s, 3H, CH_3), 1.17 (s, 3H, CH_3), 2.26 (d, J = 16.6 Hz, 1H, H-5α), 2.31 (d, J = 16.6 Hz, 1H, H-5β), 2.55 (dd, J = 2.8 Hz, J = 18.4 Hz, 1H, H-7α), 2.63 (dd, J = 1.4 Hz, J = 18.4 Hz, 1H, H-7β), 4.89 (dd, J = 2.1 Hz, J = 2.8 Hz, 1H, H-7a), 7.17-7.31 (m, 5H, 5H arom) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 28.7, 28.8, 34.4, 36.9, 46.0, 51.3, 116.9, 127.6, 127.8, 128.9, 137.4, 158.6, 171.8, 193.2 ppm; IR: ῡ = 3251 (OH), 1699 (C=O), 1628 (C=O) cm^{-1}; UV-Vis (methanol, c = 5.16·10^{-5}mol dm^{-3}): λ$_{max}$ (ε) = 207.0 (11793.72), 270.0 (10806.07) nm (mol^{-1} dm^3 cm^{-1}); MS (EI, 70 eV): m/z = 271 [M]$^+$, 254, 187, 128, 115; HRMS (EI): m/z calculated for C$_{16}$H$_{17}$NO$_3$ [M]$^+$ 271.120843, found 271.1208.

1-Hydroxy-6,6-dimethyl-3-(2-methylphenyl)-5,6,7,7a-tetrahydro-1H-indole-2,4-dione **(3b).** Isolated yield 72 %; beige crystals; m.p.: 194-196 °C (from hexane-acetone). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.15 (s, 3H, CH_3), 1.18 (s, 3H, CH_3), 2.25 (d, J = 16.2 Hz, 1H, H-5α), 2.29 (d, J = 16.2 Hz, 1H, H-5β), 2.45 (s, 3H, CH_3 arom), 2.57 (dd, J = 2.8 Hz, J = 18.3 Hz, 1H, H-7α), 2.65 (dd, J = 1.7 Hz, J = 18.3 Hz, 1H, H-5β), 5.07 (dd, J = 2.1 Hz, J = 2.8 Hz, 1H, H-7a), 6.9 (d, J = 7 Hz, 1H, CH arom), 7.08-7.15 (m, 3H, 3CH arom) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 19.8, 28.7, 28.8, 34.4, 36.9, 42.8, 51.3, 117.4, 126.5, 127.5, 131.1, 136.2, 158.9, 171.6, 192.9 ppm; IR: ῡ = 3334 (OH), 1704 (C=O), 1634 (C=O) cm^{-1}; UV-Vis (methanol, c = 4.35·10^{-5}mol dm^{-3}): λ$_{max}$ (ε) = 209.0 (16027.07), 270.5 (13451.70) nm (mol^{-1} dm^3 cm^{-1}); MS (EI, 70 eV): m/z = 285 [M]$^+$, 268, 184, 183, 141, 115; HRMS (EI): m/z calculated for C$_{17}$H$_{19}$NO$_3$ [M]$^+$ 285.1365, found 285.1377.

1-Hydroxy-3-(2-methoxyphenyl)-6,6-dimethyl-5,6,7,7a-tetrahydro-1H-indole-2,4-dione **(3c).** Isolated yield 75 %; yellowish white crystals; m.p.; 192-193 °C (from hexane-acetone). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.14 (s, 3H, CH_3), 1.15 (s, 3H, CH_3), 2.22 (d, J = 16.3 Hz, 1H, H-5α), 2.26 (d, J = 16.3 Hz, 1H, H-5β), 2.54 (dd, J = 2.8 Hz, J = 18.4 Hz, 1H, H-7α), 2.59 (dd, J = 2.1 Hz, J = 18.4 Hz, 1H, H-7β), 3.76 (s, 3H, OCH_3), 5.04 (dd, J = 1.7 Hz, J = 2.8 Hz, 1H, H-7a), 6.8-6.9 (m, 2H, 2CH arom), 7.1 (d, J = 6.0 Hz, 1H, CHarom), 7.2 (t, J = 7.0 Hz, 1H, CH arom) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 28.3, 29.1, 34.4, 37.2, 42.2, 51.3, 55.8, 111.5, 116.1, 120.9, 125.5, 129.3, 129.7, 156.9, 159.0, 171.7, 193.0 ppm; IR: ῡ = 3317 (OH), 1710 (C=O), 1669 (C=O) cm^{-1}; UV-Vis (methanol, c = 4.65·10^{-5}mol dm^{-3}): λ$_{max}$ (ε) = 204.5 (18863.64), 273.0 (13873.49) nm (mol^{-1} dm^3 cm^{-1}); MS (EI, 70 eV): m/z = 301 [M]$^+$, 284, 228, 252, 115; HRMS (EI): m/z calculated for C$_{17}$H$_{19}$NO$_4$ [M]$^+$ 301.1314, found 301.1311.

3-(2-Chlorophenyl)-1-hydroxy-6,6-dimethyl-5,6,7,7a-tetrahydro-1H-indole-2,4-dione **(3d).** Isolated yield 83 %; beige crystals; m.p.: 142-144 °C (from hexane-acetone). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.14 (s, 3H, CH_3), 1.17 (s, 3H, CH_3), 2.24 (d, J = 16.6 Hz, 1H, H-5α), 2.29 (d, J = 16.6 Hz, 1H, H-5β), 2.54 (dd, J = 2.8 Hz, J = 18.4 Hz, 1H, H-7α), 2.61 (dd, J = 1.7 Hz,

J = 18.4 Hz, 1H, *H*-7β), 5.23 (bs, 1H, *H*-7a), 7.16-7.20 (m, 3H, 3C*H* arom), 7.32-7.35 (m, 1H, C*H* arom) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 28.7, 28.9, 34.3, 36.9, 51.19, 115.6, 127.3, 129.6, 130.1, 133.4, 134.7, 157,5, 172.4, 193.0 ppm; IR: ῡ = 3321 (OH), 1707 (C=O), 1663 (C=O) cm^{-1}; UV-Vis (methanol, c = 4.85·10^{-5}mol dm^{-3}): λ$_{max}$ (ε) = 205.0 (14718.53), 270.0 (11028.59) nm (mol^{-1} dm^3 cm^{-1}); MS (EI, 70 eV): m/z = 306 [M+H]$^+$, 270, 252, 227, 196, 155, 115; HRMS (ESI): m/z calculated for C$_{16}$H$_{17}$^{35}ClNO$_3$ [M+H]$^+$ 306.08970, found 306.08917.

1-Hydroxy-6,6-dimethyl-3-(4-methylphenyl)-5,6,7,7a-tetrahydro-1H-indole-2,4-dione (3e).

Isolated yield 57 %; orange-brown crystals; m.p.: 169-171 °C (from hexane-acetone); ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.14 (s, 3H, C*H*$_3$), 1.17 (s, 3H, C*H*$_3$), 2.26-2.29 (bs, 5H, C*H*$_2$-5, C*H*$_3$ arom), 2.55 (dd, J = 2.5 Hz, J = 18.7 Hz, 1H, *H*-7α), 2.51-2.64 (m, 1H, *H*-7β), 4.85 (dd, J = 1.8, J = 2.5 Hz, 1H, *H*-7a), 7.08 (d, J = 7.8 Hz, 2H, 2C*H* arom), 7.11 (d, J = 7.8 Hz, 2H, 2C*H* arom) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 21.2, 28.7, 28.8, 34.4, 36.9, 45.7, 51.3, 117.1, 127.4, 129.7, 134.4, 137.5, 158.9, 171.7, 193.1 ppm; IR: ῡ = 3235 (OH), 1706 (C=O), 1620 (C=O) cm^{-1}; UV-Vis (methanol, c = 4.49·10^{-5}mol dm^{-3}): λ$_{max}$ (ε) = 206.0 (15014.40), 270.0 (12051.62) nm (mol^{-1} dm^3 cm^{-1}); MS (EI, 70 eV): m/z = 285 [M]$^+$, 268, 255, 201, 115; HRMS (EI): m/z calculated for C$_{17}$H$_{19}$NO$_3$ [M]$^+$ 285.1365, found 285.1368.

3-(4-Bromophenyl)-1-hydroxy-6,6-dimethyl-5,6,7,7a-tetrahydro-1H-indole-2,4-dione (3f).

Isolated yield 64 %; yellowish-orange crystals; m.p.: 96-98 °C (from hexane-acetone). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.09 (s, 3H, C*H*$_3$), 1.11 (s, 3H, C*H*$_3$), 2.18 (d, J = 16.6 Hz, 1H, *H*-5α), 2.24 (d, J = 16.6 Hz, 1H, *H*-5β), 2.51 (dd, J = 2.8 Hz, J = 18.4 Hz, 1H, *H*-7α), 2.54 (dd, J = 1.5 Hz, J = 18.4 Hz, 1H, *H*-7β), 4.82 (dd, J = 2.1, J = 2.8 Hz, 1H, *H*-7a), 7.09 (d, J = 8.5 Hz, 2H, 2C*H* arom), 7.43 (d, J = 8.5 Hz, 2H, 2C*H* arom) ppm; ^{13}C NMR (75 MHz, CDCl$_3$): δ = 28.5, 28.6, 34.4, 36.9, 44.9, 51.1, 116.6, 121.4, 129.4, 131.8, 134.5, 157.8, 172.2, 193.0 ppm; IR: ῡ = 3213 (OH), 1701 (C=O), 1645 (C=O) cm^{-1}; UV-Vis (methanol, c = 3.78·10^{-5}mol dm^{-3}): λ$_{max}$ (ε) = 204.5 (14066.97), 269.0 (10100.72) nm (mol^{-1} dm^3 cm^{-1}); MS (EI, 70 eV): m/z = 349 [M]$^+$, 334, 270, 253, 227, 155, 115, 83; HRMS (EI): m/z calculated for C$_{16}$H$_{16}$^{79}BrNO$_3$ [M]$^+$ 349.0314, found 349.0305.

Hydrogenation-dehydrogenation reactions of 3a to give products 4 and 5.

6,6-dimethyl-3-phenyl-1,2,5,6,7,7a-hexahydro-4H-indole-4-one (4).

To a suspension of Raney Nickel (400 mg) previously activated and prehydrogenated, in dry ethanol (15 mL), the compound **3a** was added (2.2 mmol) in dry ethanol (10 mL). The mixture was hydrogenated at 5 atm. until no more hydrogen is consumed. The reaction mixture was filtered on celite, the solution evaporated and the residue purified by silica gel column chromatography (hexane-ethyl acetate 90:10 as eluent), to give the product **4** (175 mg), 33 % yield; yellow crystals; m.p.: 232-234 °C (from hexane-ethyl acetate). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 0.92 (s, 3H, C*H*$_3$), 1.04 (s, 3H, C*H*$_3$), 2.00 (s, 2H, C*H*$_2$-7), 2.3 (s, 2H, C*H*$_2$-5), 3.28 (dd, J = 4.8, J = 10.5 Hz, 1H, *H*-2α), 3.95 (t, J = 11.1 Hz, H-2β), 4.15 (dd, J = 4.8, J = 11.1 Hz, 1H, H-3), 7.19-7.32 (m, 5H, 5C*H* arom) ppm, ^{13}C NMR (75 MHz, CDCl$_3$): δ = 28.0, 28.8, 33.6, 36.8, 43.4,50.5, 55.3, 105.2, 125.8, 126.8, 127.6, 139.3, 146.1, 186.4 ppm; IR (KBr): ῡ = 3396 (NH), 1587 (C=O), 11481 (C=C) cm^{-1}; MS (EI, 70 eV): m/z = 241 [M]$^+$, 240, 184, 164, 157, 128, 83. HRMS (EI): m/z calculated for C$_{16}$H$_{19}$NO [M]$^+$ 241.1466, found 241.1445.

6,6-dimethyl-3-phenyl-1,5,6,7-tetrahydro-4H-indole-4-one (5).

The compound **4** (0.5 mmol) in toluene anhydrous (10 mL) was refluxed in the presence of 10 % Pd/C (10 mg) for 3 h. The reaction mixture was filtered on celite, the solution evaporated and the residue purified by silica gel column chromatography (hexane-ethyl acetate 60:40 as eluent), to give compound **5** (52 mg), 43 % yield;white crystals; m.p.: 245-247 °C (from hexane-ethyl acetate). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.14 (s, 6H, 2xC*H*$_3$), 2.42 (s, 2H, C*H*$_2$-5), 2.2.69 (s, 2H, C*H*$_2$-7), 6.71 (s, 1H, *H*-2), 7.24 (t, J = 7.5 Hz, 1H, *H*-4′), 7.34 (t, J = 7.5 Hz, 2H, *H*-3′, *H*-5′), 7.64 (d, J = 7.5 Hz, 2H, *H*-2′, *H*-6′),7.35-7.63 (m, 5H, 5C*H* arom.) ppm, ^{13}C NMR (75 MHz, CDCl$_3$): δ = 28.6, 35.6, 37.4, 53.3, 115.9, 117.4, 125.0, 126.7, 128.0 128.7, 134.3, 144.0, 193.8 ppm; IR: ῡ = 3259 (NH), 1633 (C=O), cm^{-1}; MS (EI, 70 eV): m/z = 239 [M]$^+$, 183, 154, 125, 97, 84. HRMS (EI): m/z calculated for C$_{16}$H$_{17}$NO [M]$^+$ 239.1310, found 239.1319.

Cytotoxicity evaluation

Cancer lines were obtained from the National Cancer Institute of the United States. Cytotoxicity data were determined using the protein-bound-sulforhodamine (SRB) assay in microculture; the assay measures cell proliferation as described by Monks method [21]. Cell lines were cultivated in RPMI-1640 medium with 10 % (v/v) fetal bovine serum, 2 μM-glutamine, 100 IU/cm^{3}penicillin G, 100 mg/cm^3 streptomycin sulfate, and 0.25 μg/cm^3 of amphotericin B (Gibco Grand Island, NY). The incubation was at 37 °C in a 5 %, CO$_2$ atmosphere and 100 % relative humidity. After replication, cells were detached with a 0.05 % (w/v) trypsin-EDTA solution, counted in a hemocytometer, and diluted with complete medium to 5 x 10^3 cells/cm^3 (K-562, MCF-7), 7.5 x 10^3 cells/cm^3 (U-251, PC-3, and SKLU-1), or 10 x 10^3 cells/cm^3 (HTC-15).

Microtiter plate wells were filled with 100 mm^3 aliquots of cell suspension and incubated. After 24 h cells were treated with logarithmically diluted concentrations of sample compounds. Test samples were dissolved in DMSO to provide stock solutions (40 μM) and were then diluted to yield solutions of 100, 31, 10, 3.1 and 1 μM, for use in treatment of cell suspensions. After 48 h, cultures were fixed *in situ* by addition of 50 mm^3 50 % (w/v) trichloroacetic acid and incubated for 60 min at 4 °C. Cells were harvested by centrifugation, washed three times,

and dried. Cell pellets were suspended in 100 mm^3 0.4 % (w/v) SRB solution in 1 % (v/v) acetic acid for 30 min. Unbound SRB was removed by washing with 1 % (v/v) acetic acid and protein-linked dye was extracted with 10 μM tris(hydroxymethyl) methaneamine solution, and quantitated by spectrometry at 515 nm. The IC$_{50}$ values were calculated according to Monks [21].

Acknowledgements

References

1. Del Prete, G. Q.; Shoemaker, R.; Oswald, K.; Lara, A.; Trubey, C. M.; Fast, R.; Schneider, D. K.; Kiser, R.; Coalter, V.; Wiles, A.; Wiles, R.; Freemire, B.; Keele, B. F.; Estes, J. D.; Quiñones, O. A.; Smedley, J.; Macallister, R.; Sanchez, R. I.; Wai, J. S.; Tan, C. M.; Alvord, W. G.; Hazuda, D. J.; Piatak, M. Jr.; Lifson, J. D. *Antimicrob. Agents Chemother*. **2014**, *58*, 6790.

2. Yadav, R.; Murthy, R. V.; Kikkeri, R. *Chembiochem.* **2015**, *16*, 1448.

3. Domingo, J. L. *Reprod. Toxicol*. **1998**, *12*, 499.

4. Cabantchik, Z. I. *Parasitol. Today.* **1995,** *11*, 74.

5. Igeta, K.; Tobbeto, K.; Saiki, I.; Odake, S.; Fujisawa, T.; Matsuo, T.; Oku, T. PCT Int. App. WO 003703, 2000.

6. AndaloussI, M.; Lindh, M.; Björkelid, C; Suresh, S.; Wieckowska, A.; Iyer, H.; Karlén, A.; Larhed, M. *Bioorg. Med. Chem. Lett*. **2011**, *21*, 5403.

7. Finnin, M. S; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. *Nature* **1999**, *401*, 188.

8. Roberts, K. P.; Iyer, R. A.; Prasad, G.; Liu, L. T.; Lind, R. E.; Hanna, P. E. *Prostate*. **1998**, *34*, 92.

9. Joshi, B.; Li, L.; Taffe, B. G.; Zhu, Z.; Wahl, S.; Tian, H.; Ben-Josef, E.; Taylor, J. D.; Porter, A. T.; Tang, D. G. *Cancer Res.* **1999**, 59, 4343.

10. Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. *Cancer Res*. **2000**, *60*, 5165.

11. Cheng, P.; Chen, J. J.; Huang, N.; Wang, R. R.; Zheng, Y. T.; Liang, Y. Z. *Molecules*. **2009**, *14*, 3176.

12. Pathe, G. K.; Ahmed, N. *Tetrahedron Lett*. **2015**, *56*, 6202.

13. Kumar, M. S.; Rajanna, K. C.; Reddy, K. R.; Venkateswarlu, M.; Venkanna, P. *Synth. Commun*. **2013**, *43*, 2672.

14. Özdemir, H. S.; Şahin, E.; Çakici, M.; Kiliç, H. *Tetrahedron.* **2015**, *71*, 2882.

15. Larson, H.O.; Ooi, T. C.; Siu, A. K. Q.; Hollenbeak, K. H.; Cue, F. L. *Tetrahedron.* **1969**, *25*, 4005.

16. Tehrani, M. H. H; Farnia, M.; Nazer, M. S. *Iran. J. Pharm. Res.* **2003**, *2*, 1.

17. Basel, Y.; Hassner, A. *Synthesis*. **1997**, 309.

18. Thomas-Mendivil, E.; Suárez, F. J.; Diez, J.; Cadierno, V. *Chem. Commun*. **2014**, *50*, 9661.

19. Ishikawa, T.; Miyahara, T.; Asakura, M.; Higuchi, S.; Miyauchi, Y.; Saito, S. *Org. Lett.* **2005**, *7*, 1211.

20. The synthesis of compound **5** was carried out starting from styrene which reacts with Br$_2$ in CCl$_4$ at room temperature to give (1,2-dibromoethyl)benzene. The dibromo derivative reacts first with NaN$_3$ at room temperature and then with NaOH solution at 10 °C, both reactions in DMSO to give (1-azidoethenyl)benzene. Hortmann, A. G.; Robertson, D. A.; Gillard, B. K. *J. Org. Chem.* **1972**, *37*, 322. Afterwards, the pyrolysis of the former product at 150 °C in CH$_2$Cl$_2$ in a high pressure stainless steel reactor with hermetic seal, gives the corresponding 2*H*-azirine. Timén, Å. S.; Risberg, E.; Somfai, P. *Tetrahedron Lett*. **2003**, *44*, 5339. Treatment of the azirine with dimedone in acetone and the Ni(acac)$_2$ as the catalyst at 35-40 °C for 15 min, then 3 h at room temperature leads to the desired compound **5**. Dos Santos Fihlo, P. F.; Schuchardt, U. *Angew. Chem. Int. Ed. Engl.* **1977**, *16*, 647.

21. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. *J. Natl. Cancer Inst*. **1990**, *82*, 1107.